ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $5.61M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
1.68% more ownership
Funds ownership: 18.38% → 20.06% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $6.05M → $5.61M (-$435K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$560K |
| 2 |
VF
Virtu Financial
New York
|
+$335K |
| 3 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$168K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$145K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$40.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$243K |
| 2 |
HF
HRT Financial
New York
|
-$220K |
| 3 |
Jane Street
New York
|
-$9.7K |
BIS Hedge Fund Activity: Q3 2018 in Review
11 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2018, worth a combined $5.61M — down 7.2% from $6.05M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIS positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $560K. The largest seller was Tower Research Capital (TRC), cutting an estimated $243K.
- 11 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2018, up from 10 in Q2 2018.
- Funds reported $5.61M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2018, down 7.2% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2018 and 1 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2018 was Susquehanna International Group, an estimated $560K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2018 was Tower Research Capital (TRC), an estimated $243K sold.
Based on aggregated 13F filings for Q3 2018.